Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia

Neuropsychopharmacology

Volumn 17, Issue 6, 1997, Pages 360-369

  McCann, Una D ^a,b   Morgan, Christina M ^a   Geraci, Marilla ^a   Slate, Shiyoko O ^a   Murphy, Dennis L ^a   Post, Robert M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anxiety disorders; Cholecystokinin (CCK); Neuropeptides; Serotonin

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE; HYDROCORTISONE; ONDANSETRON; PENTAGASTRIN; PLACEBO; SEROTONIN ANTAGONIST; HORMONE;

ADULT; ANXIETY; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PANIC; PRIORITY JOURNAL; PULSE RATE; SOCIAL INTERACTION; SOCIAL PHOBIA; BEHAVIOR; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; HEMODYNAMICS; HUMAN RELATION; PATHOPHYSIOLOGY; PHOBIA; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE;

ADULT; BEHAVIOR; FEMALE; HEMODYNAMIC PROCESSES; HORMONES; HUMANS; INTERPERSONAL RELATIONS; MALE; ONDANSETRON; PANIC DISORDER; PENTAGASTRIN; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN ANTAGONISTS;

EID: 0030608701     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00085-7     Document Type: Article

References (47)

1. Abelson JL, Nesse RM, Vinik A (1991): Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. Biol Psychiatry 29:1220-1223
2. Abelson JL, Nesse RM (1994): Pentagastrin infusions in patients with panic disorder I. Symptoms and cardiovascular responses. Biol Psychiatry 36:73-83
3. Abelson JL, Nesse RM, Vinik AI (1994): Pentagastrin infusions in patients with panic disorder II. Neuroendocrinology. Biol Psychiatry 36:84-96
4. 3 antagonist, ondansetron, in social phobia. Am Coll Neuropsychopharmacol 33rd Annual Meeting, p 166
5. Bickerdike MJ, Marsden CA, Dourish CT, Fletcher A (1994): CCK antagonist effects in the rat elevated zero-maze model of anxiety: Influence of 5-HT re-uptake blockade. Eur J Pharmacol 271:403-411
6. Boden PR, Woodruff GN, Pinnock RD (1991): Pharmacology of a cholecystokinin receptor on 5-hydroxytryptamine neurons in dorsal raphe of the rat. Br J Pharmacol 102: 635-638
7. Bradwejn J, Koszycki D, Meterissian G (1990): Cholecystokinin-tetrapeptide induced panic attacks in panic disorder. Can J Phychiatry 35:83-85
8. Bradwejn J, Koszycki D, Bourin M (1991a): Dose ranging study of the effect of CCK-4 in healthy volunteers. J Psychiatr Neurosci 16(2):91-95
9. Bradwejn J, Koszycki D, Payeur R (1991b): Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder: Clinical and behavioural findings. Arch Gen Psychiatry 48:603-610
10. Charney DS, Heninger GR, Jatlow PI (1985): Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 42(3):233-243
11. Chopin P, Briley M (1993): The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 110:409-414
12. Costall B, Domeney AM, Hughes J, Kelley ME, Naylor RJ, Woodruff GN (1991): Anxiolytic effects of CCK-B antagonists. Neuropeptides 19 (Suppl):65-73
13. Crawley JN (1985): Comparative distribution of cholecystokinin and other neuropeptides. Ann NY Acad Sci 448:1-8
14. Crawley JN (1988): Behavioral analyses of antagonists of the peripheral and central effects of cholecystokinin. In Cholecystokinin Antagonists. New York, Alan R. Liss Inc, pp 243-262
15. De Montigny C (1989): Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 46:511-517
16. Degli Uberti EC, Trasforini G, Margutti AR, Rotola CA, Pansini R (1983): Effects of pentagastrin on adrenocorticotropin hormone and thyroid-stimulating hormone release in normal subjects. Horm Res 17:74-77
17. Derrien M, McCort-Tranchepain I, Ducos B, Roques BP, Durieux C (1994): Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem Behav 49:133-141
18. Dockray GJ (1976): Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 264:568-570
19. Dockray GJ, Gregory RA, Hutchinson JB, Harris JI, Runswick MJ (1977): Isolation, structure and biological activity of two cholecystokinin octapeptides from sheep brain. Nature 270:359
20. Harro J, Pold M, Vasar E (1990): Anxiogenic-like action of caerulein, a CCK-8 receptor antagonist in the mouse: Influence of acute and subchronic diazepam treatment. Naunyn-Schmiedeberg's Arch Pharmacol 341:62-67
21. Harro J, Vasar E (1991): Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol 193:379-381
22. Hartman BK, Paris PL, Kirn S-W, Eckert ED, Raymond NC, Meller WH (1995): Gastric afferent vagal hyperactivity in the pathopsysiology of bulimia nervosa. Scientific Abstracts from 1995 ACNP Annual meeting. San Juan, Puerto Rico, p 287
23. B antagonists on activity in the black/white exploration model of anxiety in mice. Psychiatry Behav 54:689-693
24. Hesketh PJ, Murphy WK, Lester EP, Gandara D, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM (1989): GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7(6):700-705
25. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter C, Pinnock RD, Woodruff GN (1990): Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732
26. Liebowitz MR, Gorman JM, Fyer AF, Levitt M, Dillon D, Levy G, Appleby IL, Anderson S, Palif M, Davies SO, Klein DF (1985): Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 42:709-719
27. Lydiard RB (1994): Neuropeptides and anxiety: Focus on cholecystokinin. Clin Chem 40(2):315-318
28. McCann UD, Slate SO, Geraci M, Uhde TW (1995): Peptides and anxiety: A dose response evaluation of pentagastrin in healthy volunteers. Anxiety 1:258-267
29. McCann UD, Slate SO, Geraci M, Roscow-Terrill D, Uhde TW (1997): A comparison of the effects of intravenous pentagastrin in patients with social phobia, panic disorder, and healthy volunteers. Neuropsychopharmacology 16(3):229-237
30. 3 antagonist, ondansetron, in panic disorder. Am Coll Neuropsychopharmacol 33rd Annual Meeting, p 165
31. Moran TH, Schwartz GJ (1994): Neurobiology of cholecystokinin. Crit Rev Neurobiol 9(1):1-28
32. 3 receptors in rat cerebral cortex and nucleus accumbens. Br J Pharmacol 25:411-414
33. Pirke KM, Kellner MB, Friess E, Krieg JC, Fichter MM (1994): Satiety and cholecystokinin. Int J Eat Disord 15(1):63-69
34. Ravard S, Dourish CT (1991): Cholecystokinin and anxiety. Trends Pharmacol Sci 11:271-273
35. Rex A, Fink H, Marsden CA (1994): Effects of BOC-CCK-4 and L 365,260 and cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology 33:559-565
36. Roila F, Del Favero AD (1995): Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 29(2):95-109
37. Schleyer B, Aarons C, Mannuzza S, Martin L, Fyer AJ (1990): Schedule for Affective Disorders and Schizophrenia Lifetime Version Modified for the Study of Anxiety Disorders (updated for DSM-III-R). New York.
38. B receptor antagonist. Br J Pharmacol 104:239-245
39. Spielberger CD, Gorsuch RW, Lushene RE (1970): State-Trait Anxiety Inventory. Palo Alto, CA, Consulting Psychologists Press, Inc
40. Van Megen HJGM, Westenberg HGM, den Boer JA, Haigh JRM, Traub M (1994): Pentagastrin induced panic attacks: Enhanced sensitivity in panic disorder patients. Psychopharmacology 114:449-455
41. Vanderhaeghen JJ, Lostra F, Vierendeels G, Gilles C, Deschepper C, Verbanck P (1981): Cholecystokinins in the central nervous system of neurohypophysis. Peptides 2:81-88
42. 3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology 110:213-218
43. Vasar E, Lang A, Harro J, Bourin M, Bradwejn J (1994): Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology 33:729-735
44. Woods SW, Goodman WK, Charney DS (1986): NE Hyperactivity Associated with Yohimbine Panic. Washington, DC, American Psychiatric Association
45. Woods SW, Charney DS, Goodman WK, Heninger GR (1988): Carbon dioxide-induced anxiety: Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy volunteers. Arch Gen Psychiatry 45:43-52
46. Woolson RF (1987): Comparing more than two groups of observations: Analysis of variance for comparing groups. In Woolson RF (ed), Statistical Methods for the Analysis of Biomedical Data. New York, John Wiley and Sons, pp 314-363
47. Zung WWK (1971): A rating instrument for anxiety disorders. Psychosomatics 12:371-379